Nicola Giuliani

List of Publications by Year
in descending order

177 papers	7,129 citations	50244 46 h-index	62565 80 g-index
181 all docs	181 docs citations	181 times ranked	7624 citing authors

#	Article	IF	Citations
1	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	15.2	26
2	Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?. Acta Haematologica, 2021, 144, 302-307.	0.7	4
3	PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression. Cancers, 2021, 13, 164.	1.7	15
4	Oncolytic Virotherapy and Microenvironment in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 2259.	1.8	1
5	How<i>Euglena gracilis</i>swims: Flow field reconstruction and analysis. Physical Review E, 2021, 103, 023102.	0.8	6
6	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 2021, 11, 73.	2.8	7
7	A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. Vaccines, 2021, 9, 389.	2.1	30
8	The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes. Applied Sciences (Switzerland), 2021, 11, 4642.	1.3	2
9	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood, 2021, 137, 3027-3036.	0.6	40
10	Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets. Cells, 2021, 10, 1360.	1.8	19
11	Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Frontiers in Oncology, 2021, 11, 684561.	1.3	12
12	Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?. Transplant International, 2021, 34, 2442-2458.	0.8	2
13	[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma. Frontiers in Oncology, 2021, 11, 760732.	1.3	9
14	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica, 2020, 105, 1074-1080.	1.7	16
15	Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1238-1241.	0.6	2
16	Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy. Journal of Hematology and Oncology, 2020, 13, 89.	6.9	13
17	Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability. Cancers, 2020, 12, 3267.	1.7	22
18	The Circular Life of Human CD38: From Basic Science to Clinics and Back. Molecules, 2020, 25, 4844.	1.7	17

#	Article	IF	Citations
19	Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3022.	1.0	12
20	Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies. Journal of Clinical Medicine, 2020, 9, 2864.	1.0	7
21	Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. Cancers, 2020, 12, 1332.	1.7	7
22	CD14 + CD16 + monocytes are involved in daratumumabâ€mediated myeloma cells killing and in antiâ€CD47 therapeutic strategy. British Journal of Haematology, 2020, 190, 430-436.	1.2	18
23	Functional Consequences of Low Activity of Transport System A for Neutral Amino Acids in Human Bone Marrow Mesenchymal Stem Cells. International Journal of Molecular Sciences, 2020, 21, 1899.	1.8	6
24	PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients. Frontiers in Immunology, 2020, 11, 613007.	2.2	12
25	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. Frontiers in Immunology, 2020, 11, 573156.	2.2	8
26	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight, 2020, 5, .	2.3	43
27	Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial. Blood, 2020, 136, 38-40.	0.6	22
28	Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts. Blood, 2020, 136, 20-21.	0.6	1
29	Editorial: Immunotherapy in Multiple Myeloma. Frontiers in Immunology, 2019, 10, 1945.	2.2	7
30	Haploidentical hematopoietic stem cell transplantation in adults using the Î±Î²TCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells. Bone Marrow Transplantation, 2019, 54, 698-702.	1.3	8
31	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Journal of Hematology and Oncology, 2019, 12, 4.	6.9	27
32	Novel targets for the treatment of relapsing multiple myeloma. Expert Review of Hematology, 2019, 12, 481-496.	1.0	25
33	The transcriptomic profile of CD138⁺ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. Haematologica, 2019, 104, e465-e469.	1.7	8
34	Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. Cancers, 2019, 11, 261.	1.7	11
35	Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. Cancers, 2019, 11, 321.	1.7	24
36	CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents. Cells, 2019, 8, 1632.	1.8	28

#	Article	IF	Citations
37	BlackNUFFT: Modular customizable black box hybrid parallelization of type 3 NUFFT in 3D. Computer Physics Communications, 2019, 235, 324-335.	3.0	0
38	Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. Journal of Hematology and Oncology, 2019, 12, 2.	6.9	88
39	The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38. Immunology Letters, 2019, 205, 65-70.	1.1	11
40	Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease. Blood, 2019, 134, 4339-4339.	0.6	0
41	Possible targets to treat myeloma-related osteoclastogenesis. Expert Review of Hematology, 2018, 11, 325-336.	1.0	9
42	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD⁺. OncoImmunology, 2018, 7, e1458809.	2.1	59
43	Ï€-BEM: A flexible parallel implementation for adaptive, geometry aware, and high order boundary element methods. Advances in Engineering Software, 2018, 121, 39-58.	1.8	15
44	The Proteasome and Myeloma-Associated Bone Disease. Calcified Tissue International, 2018, 102, 210-226.	1.5	15
45	Bone marrow Dikkopfâ€1 levels are a new independent risk factor for progression in patients with smouldering myeloma. British Journal of Haematology, 2018, 183, 812-815.	1.2	5
46	Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy. Frontiers in Immunology, 2018, 9, 2467.	2.2	31
47	Neurofibromatosis type I and multiple myeloma coexistence: A possible link?. Hematology Reports, 2018, 10, 7457.	0.3	1
48	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722.	2.2	124
49	Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis. Journal of Hematology and Oncology, 2018, 11, 123.	6.9	10
50	deal2lkit: A toolkit library for high performance programming in deal.II. SoftwareX, 2018, 7, 318-327.	1.2	13
51	Predicting and Optimizing Microswimmer Performance from the Hydrodynamics of Its Components: The Relevance of Interactions. Soft Robotics, 2018, 5, 410-424.	4.6	17
52	A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis. Case Reports in Hematology, 2018, 2018, 1-5.	0.3	5
53	Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood, 2018, 132, 1798-1798.	0.6	4
54	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. Blood, 2018, 132, 2023-2023.	0.6	0

#	Article	IF	Citations
55	TBK1/IkkÎμ Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo. Blood, 2018, 132, 4504-4504.	0.6	1
56	Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients. Blood, 2018, 132, 3183-3183.	0.6	0
57	The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma. Expert Opinion on Therapeutic Targets, 2017, 21, 231-234.	1.5	18
58	<i>IL21R</i> expressing CD14 ⁺ CD16 ⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784.	1.7	36
59	GPNA inhibits the sodium-independent transport system l for neutral amino acids. Amino Acids, 2017, 49, 1365-1372.	1.2	72
60	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell, 2017, 32, 88-100.e6.	7.7	114
61	Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. International Journal of Hematology, 2017, 105, 104-108.	0.7	14
62	Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide. Blood Advances, 2017, 1, 2166-2175.	2.5	16
63	Role of Galectins in Multiple Myeloma. International Journal of Molecular Sciences, 2017, 18, 2740.	1.8	21
64	Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget, 2017, 8, 56598-56611.	0.8	52
65	Assessment of the interlaboratory variability and robustness of <i>JAK2</i>V617F mutation assays: A study involving a consortium of 19 Italian laboratories. Oncotarget, 2017, 8, 32608-32617.	0.8	5
66	Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget, 2017, 8, 53053-53067.	0.8	27
67	Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma. Molecular Medicine, 2016, 22, 694-704.	1.9	81
68	The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors. Journal of Bone and Mineral Research, 2016, 31, 815-827.	3.1	52
69	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood, 2016, 127, 1102-1108.	0.6	78
70	Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood, 2016, 128, 667-679.	0.6	128
71	The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1Â inhibition in myeloma cells. Haematologica, 2016, 101, e107-e110.	1.7	11
72	Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia, 2016, 30, 2351-2363.	3.3	29

#	Article	IF	Citations
73	Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. Leukemia, 2016, 30, 409-416.	3.3	55
74	Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells. Blood, 2016, 128, 4422-4422.	0.6	1
75	Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients. Blood, 2016, 128, 4647-4647.	0.6	2
76	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697.	0.6	2
77	ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood, 2016, 128, 359-359.	0.6	0
78	Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML. Blood, 2016, 128, 4302-4302.	0.6	0
79	Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively. Blood, 2016, 128, 4464-4464.	0.6	0
80	NAD+-Metabolizing Ectoenzymes in Remodeling Tumorâ€"Host Interactions: The Human Myeloma Model. Cells, 2015, 4, 520-537.	1.8	99
81	Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. BioMed Research International, 2015, 2015, 1-13.	0.9	87
82	The osteoblastic niche in the context of multiple myeloma. Annals of the New York Academy of Sciences, 2015, 1335, 45-62.	1.8	49
83	Myeloma and osteoclast relationship. , 2015, , 491-500.		0
84	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015, 27, 644-657.	7.7	85
85	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences, 2015, 1335, 10-22.	1.8	47
86	FEM SUPG stabilisation of mixed isoparametric BEMs: Application to linearised free surface flows. Engineering Analysis With Boundary Elements, 2015, 59, 8-22.	2.0	8
87	Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. Blood, 2015, 126, 1849-1849.	0.6	16
88	Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity. Blood, 2015, 126, 2959-2959.	0.6	1
89	The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4. Blood, 2015, 126, 5315-5315.	0.6	0
90	CD38 and bone marrow microenvironment. Frontiers in Bioscience - Landmark, 2014, 19, 152.	3.0	26

#	Article	IF	Citations
91	Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia, 2014, 28, 951-954.	3.3	49
92	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097.	3.3	14
93	Extended and reduced POG dynamic model of an automatic corking machine for threaded plastic caps. Mechatronics, 2014, 24, 1-11.	2.0	5
94	Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Experimental Hematology, 2013, 41, 387-397.e1.	0.2	65
95	Bisphosphonates in Multiple Myeloma: Preclinical and Clinical Data. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 113-121.	1.3	4
96	Hypoxia-inducible factor (HIF)-1Î± suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia, 2013, 27, 1697-1706.	3.3	104
97	Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia, 2013, 27, 451-463.	3.3	48
98	New Insights into Osteogenic and Chondrogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells and Their Potential Clinical Applications for Bone Regeneration in Pediatric Orthopaedics. Stem Cells International, 2013, 2013, 1-11.	1.2	71
99	Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL. Blood, 2013, 122, 2641-2653.	0.6	17
100	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, 122, 1376-1383.	0.6	74
101	Myeloma-Induced Osteocyte Death Was Blunted By Proteasome Inhibitors Through The Modulation Of Autophagy. Blood, 2013, 122, 3096-3096.	0.6	1
102	Relationship Between Presence Of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels Of Cytokines and Chemokines In Multiple Myeloma Patients: Role Of Chemokine (C-C motif) Ligand 20. Blood, 2013, 122, 3110-3110.	0.6	0
103	IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A. Blood, 2013, 122, 3101-3101.	0.6	5
104	Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia, 2012, 26, 1391-1401.	3.3	116
105	Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients. Blood, 2012, 120, 3978-3978.	0.6	3
106	Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. Blood, 2012, 120, 446-446.	0.6	6
107	Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo.. Blood, 2012, 120, 2947-2947.	0.6	0
108	CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment. Blood, 2012, 120, 444-444.	0.6	0

#	Article	IF	Citations
109	Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance. Blood, 2012, 120, 1811-1811.	0.6	0
110	Dynamic modeling and control of a new automatic corking machine for threaded plastic caps. , 2011, , .		1
111	HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia, 2011, 25, 527-537.	3.3	39
112	The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Experimental Hematology, 2011, 39, 55-65.	0.2	7
113	Angiogenesis and Multiple Myeloma. Cancer Microenvironment, 2011, 4, 325-337.	3.1	88
114	Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells. Clinical Cancer Research, 2011, 17, 6963-6970.	3.2	17
115	Hypoxia-Inducible Factor (HIF)-1Î± Is a Therapeutic Target in Myeloma-Induced Angiogenesis. Blood, 2011, 118, 3927-3927.	0.6	2
116	Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effects of IL-3 in Myeloma,. Blood, 2011, 118, 3933-3933.	0.6	6
117	The Activation of Wnt5a-Mediated Non Canonical Wnt Signaling in Human Bone Marrow Osteoprogenitor Cells Increases Osteoblastogenesis and Counterbalances the Inhibitory Effect of Myeloma Cells on Ror2/FZD5 Expression,. Blood, 2011, 118, 3928-3928.	0.6	0
118	Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Experimental Hematology, 2010, 38, 141-153.	0.2	57
119	Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia, 2010, 24, 1368-1370.	3.3	8
120	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. Journal of Clinical Oncology, 2010, 28, 800-807.	0.8	166
121	Low bone marrow oxygen tension and hypoxia-inducible factor-1Î± overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia, 2010, 24, 1967-1970.	3.3	107
122	Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma. Clinical Cancer Research, 2010, 16, 4188-4197.	3.2	88
123	In Vitro and In Vivo Evidences of Osteocyte Involvement In Myeloma-Induced Osteolysis. Blood, 2010, 116, 131-131.	0.6	2
124	The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio In Myeloma Microenvironment Targeting the Expression of Adhesion Molecules. Blood, 2010, 116, 448-448.	0.6	1
125	Mechanisms Involved in Osteoblast Suppression in Multiple Myeloma. , 2010, , 231-242.		0
126	Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma. Blood, 2010, 116, 4059-4059.	0.6	0

#	Article	IF	Citations
127	Impact of XIAP protein levels on the survival of myeloma cells. Haematologica, 2009, 94, 87-93.	1.7	34
128	Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: Identification of potential therapeutic targets. Experimental Hematology, 2009, 37, 879-886.	0.2	43
129	Gene array profile identifies collagen type XV as a novel human osteoblastâ€secreted matrix protein. Journal of Cellular Physiology, 2009, 220, 401-409.	2.0	30
130	Oxygen Tension in the Bone Marrow (BM) of Patients with Malignant and Indolent Monoclonal Gammopathy: Role of Hypoxia and Hypoxia-Inducible Factor (HIF)-1Î± in the Regulation of Gene Expression and Pro-Angiogenic Profiles of CD138+ Cells.. Blood, 2009, 114, 422-422.	0.6	1
131	Increased Osteocyte Apoptosis in Multiple Myeloma Patients: A Potential Role in Bone Remodeling Alterations Related to Osteolytic Bone Lesions.. Blood, 2009, 114, 830-830.	0.6	0
132	Are the Myeloma Bone Microevironment Cells Tumoral or Not?.. Blood, 2009, 114, 1816-1816.	0.6	0
133	Myeloma Cells Inhibit the Non-Canonical Wnt Co-Receptor Ror2 in Human Mesenchymal/Osteoprogenitor Cells: Effect of Wnt5a/Ror2 Pathway Activation On MM-Induced Impairment of the Osteogenic Differentiation Process.. Blood, 2009, 114, 741-741.	0.6	0
134	Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.. Blood, 2009, 114, 1837-1837.	0.6	0
135	HOXB7 Is Critically Involved in Multiple Myeloma-Induced Angiogenic Switch.. Blood, 2009, 114, 125-125.	0.6	0
136	CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3Î± and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions. Cancer Research, 2008, 68, 6840-6850.	0.4	68
137	Constitutive expression of IL-12RÎ²2 on human multiple myeloma cells delineates a novel therapeutic target. Blood, 2008, 112, 750-759.	0.6	38
138	Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood, 2008, 112, 2450-2462.	0.6	73
139	Hypoxia and Hypoxia Inducible Factor (HIF)-1Î± in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment.. Blood, 2008, 112, 1687-1687.	0.6	12
140	Proteasome Stress Causes Apoptotic Sensitivity of Multiple Myeloma Cells to Proteasome Inhibition. Blood, 2008, 112, 247-247.	0.6	2
141	Activation of Non-Canonical Wnt Pathway in Human Mesenchymal Cells Affects Osteogenic Differentiation: A Potential Target in Multiple Myeloma Microenvironment. Blood, 2008, 112, 2742-2742.	0.6	1
142	HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis. Blood, 2008, 112, 2743-2743.	0.6	0
143	Bone Microenvironment Cells Show a Different Pattern of Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions in Multiple Myeloma Patients. Blood, 2008, 112, 2740-2740.	0.6	0
144	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€"Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	0.8	301

#	ARTICLE	IF	CITATIONS
145	Elevated Tumor Necrosis Factor-<i>Î±</i>Suppresses TAZ Expression and Impairs Osteogenic Potential of Flk-1⁺Mesenchymal Stem Cells in Patients with Multiple Myeloma. Stem Cells and Development, 2007, 16, 921-930.	1.1	68
146	Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment. Cancer Research, 2007, 67, 7665-7674.	0.4	102
147	The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood, 2007, 110, 334-338.	0.6	241
148	The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 Î± (HIF-1Î±) activity: involvement in myeloma-induced angiogenesis. Blood, 2007, 110, 4464-4475.	0.6	117
149	Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma. Leukemia and Lymphoma, 2007, 48, 2323-2329.	0.6	46
150	Macrophage Inflammatory Protein (MIP)-3Î±/CCL20 and Its Receptor CCR6 Are Overexpressed in the Bone Microenvironment and Involved in Osteoclast Formation in Multiple Myeloma Patients.. Blood, 2007, 110, 3510-3510.	0.6	1
151	Biology and Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2006, 12, 81-86.	2.0	10
152	Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood, 2006, 107, 841-842.	0.6	45
153	Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood, 2006, 108, 3992-3996.	0.6	279
154	Targeting Pathways Mediating Bone Disease. Current Pharmaceutical Biotechnology, 2006, 7, 423-429.	0.9	5
155	CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica, 2006, 91, 1489-97.	1.7	59
156	Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 2005, 106, 2472-2483.	0.6	289
157	IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 2005, 106, 1407-1414.	0.6	187
158	Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia, 2005, 19, 2166-2176.	3.3	64
159	OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?. Clinical Rheumatology, 2005, 24, 296-300.	1.0	37
160	Angiopoietin-1 and Myeloma-Induced Angiogenesis. Leukemia and Lymphoma, 2005, 46, 29-33.	0.6	7
161	Immunohistologic Identification and Quantification of Human Bone Marrow Hematopoietic Stem Cells.. Blood, 2005, 106, 2301-2301.	0.6	0
162	Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells. Haematologica, 2005, 90, 275-8.	1.7	19

#	Article	IF	Citations
163	Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia, 2004, 18, 628-635.	3.3	75
164	New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-Î°B ligand (RANKL). Experimental Hematology, 2004, 32, 685-691.	0.2	108
165	Angiogenic Switch in Multiple Myeloma. Hematology, 2004, 9, 377-381.	0.7	24
166	The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica, 2004, 89, 1118-23.	1.7	23
167	Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood, 2003, 102, 638-645.	0.6	103
168	Do human myeloma cells directly produce basic FGF?. Blood, 2003, 102, 3071-3073.	0.6	17
169	Human myeloma cells stimulate the receptor activator of nuclear factor-Î°B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 2002, 100, 4615-4621.	0.6	241
170	Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood, 2001, 98, 3527-3533.	0.6	374
171	Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Experimental Gerontology, 2001, 36, 547-557.	1.2	136
172	Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology, 2000, 143, 197-202.	1.9	117
173	Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomyin vivoand decrease its release in human osteoblastic cellsin vitro. Clinical Endocrinology, 1999, 51, 801-807.	1.2	40
174	Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulinâ€dependent diabetes. Journal of Internal Medicine, 1998, 243, 43-48.	2.7	0
175	Bisphosphonates Stimulate Formation of Osteoblast Precursors and Mineralized Nodules in Murine and Human Bone Marrow Cultures In Vitro and Promote Early Osteoblastogenesis in Young and Aged Mice In Vivo. Bone, 1998, 22, 455-461.	1.4	245
176	Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2976-2979.	1.8	117
177	Microrom: An efficient and accurate reduced order method to solve many-query problems in micro-motility Â. ESAIM: Mathematical Modelling and Numerical Analysis, 0, , .	0.8	0